Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CareCloud ( (CCLD) ) is now available.
On May 7, 2026, CareCloud reported first-quarter 2026 results showing revenue of $31.3 million, up 13% year over year from $27.6 million, alongside its eighth consecutive quarter of positive GAAP net income, though profit dipped to $922,000 from $1.9 million and adjusted EBITDA edged down to $5.4 million from $5.6 million. The company said earnings were temporarily pressured by elevated amortization and one-time integration costs tied to its August 2025 Medsphere acquisition and other 2025 deals, and it expects margins to improve as these non-recurring items subside.
Management highlighted a simplified capital structure following the closing of a $50 million credit facility and the scheduled full cash redemption of its Series B preferred stock on May 15, 2026, moves that are intended to strengthen the balance sheet and clarify the equity base. Operationally, CareCloud expanded into the inpatient software market with inpatient EHR, revenue cycle and analytics offerings built around its top-ranked emergency department platform, and formally launched an AI Center of Excellence, including the stratusAI Desk Agent that now automates about 75% of inbound patient calls and the stratusAI Voice Audit tool that identifies revenue and compliance opportunities in real time.
The company reaffirmed its full-year 2026 guidance, projecting revenue of $128 million to $132 million, adjusted EBITDA of $29 million to $31 million and GAAP EPS of $0.20 to $0.23, implying a doubling or more of earnings per share versus 2025. By maintaining its outlook despite near-term integration drag and investing in AI capabilities that management says create a technology-led competitive advantage, CareCloud is signaling confidence in resumed margin expansion and its ability to scale AI-driven revenue across a larger addressable market, a stance that will be closely watched by investors and healthcare clients alike.
The most recent analyst rating on (CCLD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CareCloud stock, see the CCLD Stock Forecast page.
Spark’s Take on CCLD Stock
According to Spark, TipRanks’ AI Analyst, CCLD is a Neutral.
The score is driven mainly by improved financial performance and strong cash generation with low leverage, reinforced by upbeat 2026 guidance and positive capital-structure moves. These strengths are partially offset by weak current technical momentum and a demanding valuation (high P/E), alongside execution/integration risks highlighted on the earnings call.
To see Spark’s full report on CCLD stock, click here.
More about CareCloud
CareCloud, Inc., listed on Nasdaq under tickers CCLD and CCLDO, is a U.S. provider of AI-powered healthcare technology and revenue cycle management solutions serving medical practices and health systems nationwide. Its portfolio spans revenue cycle management, practice management, electronic health records, business intelligence, patient experience management and digital health tools, supporting more than 45,000 providers in improving clinical workflows and financial performance.
The company emphasizes combining disciplined innovation with automation to streamline administrative tasks and reduce operating costs for healthcare organizations. By layering AI-driven services onto an expanded ambulatory and inpatient software platform, including a top-ranked emergency department information system, CareCloud aims to deliver a full-stack technology offering that scales across care settings and enhances patient experience while boosting provider margins.
Average Trading Volume: 510,116
Technical Sentiment Signal: Buy
Current Market Cap: $127.1M
Learn more about CCLD stock on TipRanks’ Stock Analysis page.